Latest studies
- CompletedNot Applicable
Finding out the genetic cause of Juvenile Myoclonic Epilepsy
This study aims to find the genetic causes of Juvenile Myoclonic Epilepsy (JME). Researchers are comparing DNA and brainwave tests (EEGs) from people with JME to people without epilepsy. The goal is to better understand JME, potentially helping scientists develop more targeted and personalised treatments in the future.
People with a diagnosis of Juvenile Myoclonic EpilepsyEstonia - CompletedPhase III
Prevention of complications to Improve outcome in elderly patients with acute stroke - A randomised clinical trial
This clinical trial looks at whether giving common medicines right after a stroke can prevent complications like fever, sickness, and chest infections before they start. Researchers want to see if treating older adults early with paracetamol, antibiotics, or anti-sickness medicine helps them recover better and stay independent.
Acute ischaemic stroke or intracerebral haemorrhageEstonia - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy
This study tests a medicine called Vyvgart in adults with Sjögren's disease who have nerve damage in their hands, legs, or feet. Researchers want to see if regular injections under the skin can ease nerve symptoms, reduce fatigue, and be used safely compared with a dummy treatment.
Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (SMPN) or Sensory Polyneuropathy (SPN)Estonia - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2b, randomized, placebo-controlled, observer-blind study in adults 60 years and older to evaluate the efficacy, safety, and immunogenicity of a bivalent protein vaccine candidate against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)
This clinical trial is testing a new combination vaccine designed to protect older adults against two common chest viruses: RSV and HMPV. Researchers want to find out how well the vaccine prevents lung infections, how safe it is, and whether it helps the immune system build strong protective defences.
Infections and infestationsEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low Grade (LG) Nonmuscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA)
This phase 3 study tests a new treatment called UGN-103 for non-muscle invasive bladder cancer. UGN-103 is a medicine placed directly into the bladder to help clear early-stage cancer cells. Researchers want to see how well it works, how safe it is, and if it can reduce the need for surgery.
Nonmuscle Invasive Bladder CancerEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease
This study tests whether a medicine called efgartigimod can help adults with primary Sjögren’s disease. Researchers want to see if regular injections under the skin can ease symptoms like joint pain, dry eyes, and dry mouth, and lower overall body inflammation compared with a dummy treatment (placebo).
Primary Sjögren’s DiseaseEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy (PROTECT)
This phase 3 clinical study tests a new medicine called sparsentan for adults with IgA nephropathy, a serious kidney condition. Researchers want to see if sparsentan is better at reducing protein leaks in urine and protecting kidney function over time compared to a standard medicine called irbesartan.
Immunoglobulin A Nephropathy (IgAN)Estonia - RecruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients
This study tests a new medicine called FYB206 for adults who have had advanced skin cancer (melanoma) removed by surgery. Researchers want to check if FYB206 behaves in the body in the exact same way as Keytruda, an approved immunotherapy drug used to help stop cancer returning.
Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resectionEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
This study looks at a new drug called nemolizumab for adults with moderate-to-severe eczema (atopic dermatitis). Researchers want to see how safe the medicine is when used over a long period. They also want to find out how well it clears skin, calms itchiness, and improves sleep.
Atopic DermatitisEstonia - AuthorisedPhase III and phase IV (Integrated)
A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants with Primary Biliary Cholangitis (PBC)
This study is looking at a medicine called saroglitazar magnesium for people living with primary biliary cholangitis (PBC). Researchers want to see if this daily tablet can protect the liver from long-term damage, reduce extreme tiredness, and lower the risk of serious complications or needing a liver transplant.
Primary Biliary Cholangitis (PBC)Estonia - RecruitingTherapeutic confirmatory (Phase III)
Randomized, Observer-Blind, Active-Controlled, Phase III Study in Adults ≥ 60 years of Age to Assess the Safety and Immunogenicity of Abbott’s Candidate High-Dose Influenza Vaccine.
This study tests a new high-dose flu vaccine designed for older adults. As we age, our immune systems need extra help to fight off illness. Researchers want to see if this new jab safely creates strong protection against three flu strains compared to existing flu vaccines.
Influenza immunisationEstonia - AuthorisedTherapeutic confirmatory (Phase III)
A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)
This clinical trial is testing new blood-thinning medicines for adults with peripheral artery disease who recently had a procedure to restore blood flow in their legs. Researchers want to find out if these medicines can prevent serious blood clots, heart attacks, and amputations without causing major bleeding problems.
Peripheral Artery DiseaseEstonia - AuthorisedTherapeutic confirmatory (Phase III)
Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)
This phase 3 trial looks at whether an immunotherapy drug called durvalumab helps people with limited-stage small cell lung cancer live longer. It tests if giving durvalumab through a drip after standard chemotherapy and radiotherapy helps keep the cancer from returning.
Small-cell lung cancer, limited stageEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type
This study is testing a new medicine, AVP-786, for people with Alzheimer's disease who experience agitation. It aims to see if the medicine can help reduce agitation and if it's safe to use. Some people will get the medicine, and others will get a dummy pill.
Agitation in Patients With Dementia of the Alzheimer's TypeEstonia - RecruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/II, observer-blind, randomised, placebo-controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an HSV-targeted immunotherapy in healthy participants aged 18-40 years or in participants aged 18-60 years with recurrent genital herpes.
This study is testing a new treatment for herpes simplex (the virus that causes cold sores and genital herpes). It looks at how safe the treatment is, any side effects, and if it helps people with recurrent genital herpes, comparing it to a dummy treatment.
Herpes SimplexEstonia - RecruitingTherapeutic exploratory (Phase II)
A 5- year randomized, double-blind, placebo-controlled, multi-center study assessing the efficacy, safety, and tolerability of intra-articular regimens of LNA043 versus placebo in patients with symptomatic knee osteoarthritis (ONWARDS)
This 5-year study is looking at a new medicine, LNA043, for knee osteoarthritis. It compares LNA043 to a dummy treatment (placebo) to see if it improves knee structure and reduces pain and stiffness for people aged 18 and over.
OsteoarthritisEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
This study is looking at a new treatment for stomach cancer and cancer where the food pipe joins the stomach. It's comparing a drug called pembrolizumab combined with chemotherapy against chemotherapy alone, to see if it helps patients live longer and stops the cancer from coming back.
Gastric and gastroesophageal junction (GEJ) adenocarcinomaEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
This study looks at a new medicine called tildrakizumab (also known as Ilumetri) for people with psoriatic arthritis who haven't responded well to other treatments. It aims to see if tildrakizumab can help reduce joint pain and swelling better than a dummy medicine.
Psoriatic ArthritisEstonia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid
This study is testing new combinations of medicines for a liver condition called Primary Biliary Cholangitis (PBC). We want to see if these combinations are safe and work better than current treatments, especially for people who haven't responded well to their usual medication.
Primary Biliary Cholangitis (PBC)Estonia - RecruitingTherapeutic use (Phase IV)
Efficacy, safety, tolerability and quality of life of ongoing individually optimized lipid-lowering therapy with or without inclisiran (KJX839) – a randomized, placebo-controlled, double-blind multicenter phase IV study in participants with hypercholesterolemia
This study is looking at a new way to lower 'bad' cholesterol (hypercholesterolemia). It compares a new medicine called Inclisiran with usual treatments, to see if it's safe and helps people feel better and reach their cholesterol goals.
HypercholesterolemiaEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults with Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype
This study looks at a new treatment called Diamyd for teenagers and adults recently diagnosed with Type 1 diabetes. Researchers want to see if it can help preserve the body's natural ability to make insulin. It’s a major study to check how well it works and if it's safe.
Type 1 diabetes mellitusEstonia - RecruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
This study is testing a new medicine, SAR442168, for people with Primary Progressive Multiple Sclerosis (PPMS). It's comparing the new medicine to a dummy pill to see if it can slow down the disease's progress and if it's safe to use.
Primary Progressive Multiple SclerosisEstonia - RecruitingTherapeutic exploratory (Phase II)
A randomized, multi-centric, placebo-controlled, participant and investigator-blinded study to evaluate the safety, tolerability and efficacy of TIN816 in adult patients at risk for acute kidney injury following cardiac surgery
This study is testing a new medicine, TIN816, for adults having heart surgery. It aims to see if TIN816 can protect kidneys from injury, which can sometimes happen after such operations. Researchers are checking how safe and effective the medicine is.
Acute kidney injuryEstonia - RecruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
Giant cell arteritis (GCA)Estonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study is testing a new treatment called OPT-302, given alongside an existing treatment (Eylea), for a serious eye condition called 'wet' Age-related Macular Degeneration (AMD). Doctors want to see if combining these treatments helps people see better than Eylea alone.
Neovascular Age-related Macular Degeneration (wet AMD)Estonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults (OP0595-5)
This study is testing new medicines for serious urine infections. It compares them to a standard medicine to see if they are safe and work well for adults with complicated urine infections or kidney infections, checking if they clear the infection and make patients feel better.
Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)Estonia - RecruitingTherapeutic confirmatory (Phase III)
Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)
This study is looking into a new treatment called itepekimab for people with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It will compare the new drug to a dummy treatment to see if it helps reduce flare-ups of COPD and improves lung function in former smokers.
Chronic Obstructive Pulmonary DiseaseEstonia - RecruitingTherapeutic confirmatory (Phase III)
A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500μg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis
This study looks at new inhaled medications for people with a type of lung disease called COPD. It aims to see if these new medicines can help reduce flare-ups, improve breathing, and make everyday life better.
Chronic Obstructive Pulmonary Disease (COPD)Estonia - RecruitingTherapeutic confirmatory (Phase III)
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
This study is testing a new medicine, BI 1015550, for people with progressive fibrosing interstitial lung diseases (PF-ILDs). Researchers want to see if it helps improve lung function and is safe to use over about a year.
Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Estonia - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)
This study is testing a new medication called Sparsentan for people with a kidney condition called FSGS. It compares Sparsentan to an existing treatment (Irbesartan) to see how well it protects the kidneys and if it's safe over about two years.
Focal segmental glomerulosclerosis (FSGS)Estonia - RecruitingTherapeutic exploratory (Phase II)
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
This study looks at a new medicine called BH-200 for adults with severe depression. It compares BH-200 to a dummy pill to see if it helps improve mood and daily life better, and if it's safe.
Major Depressive DisorderEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking into a new treatment called Efgartigimod for Thyroid Eye Disease (TED). Researchers want to see how well it works, if it's safe, and if it causes any side effects. It's a big study involving many people, with some receiving the new drug and others a dummy treatment.
Thyroid Eye Disease (TED)Estonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age
This study is testing a new mRNA flu vaccine for adults aged 50 and over. Researchers want to see how safe and effective it is compared to a standard flu jab. It aims to protect against the flu and understand how the body reacts to the new vaccine.
InfluenzaEstonia - RecruitingTherapeutic confirmatory (Phase III)
Effect of ALlopurinol in addition to hypothermia for hypoxicischemic Brain Injury on Neurocognitive Outcome
This study is looking at whether a medicine called allopurinol, when given with usual cooling treatment, can help babies who have suffered a specific type of brain injury around birth. Researchers want to see if it improves their development and reduces serious problems by age two.
Brain injury termed “hypoxic-ischemic encephalopathy” (HIE) as a result of various events during labour and childbirth such as placental abruption, uterine rupture, umbilical cord complications, etc.)Estonia - RecruitingTherapeutic exploratory (Phase II)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SCD-044 IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS
This study is testing a new medicine, SCD-044, for people with moderate to severe eczema (atopic dermatitis). Researchers want to see if different doses of this medicine are safe and help improve eczema symptoms by a lot.
atopic dermatitisEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
This study is testing a new medicine, ESK-001, for people with moderate to severe plaque psoriasis. Researchers want to see if it's safe and helps clear up skin patches better than a dummy pill or an existing medicine (Otezla).
Moderate to Severe Plaque PsoriasisEstonia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis
This study looks at a new drug combination for Primary Biliary Cholangitis (PBC). It checks if mixing two existing medicines, Obeticholic Acid and Bezafibrate, helps liver health over a long time. Researchers want to see how safe and effective this combination is for patients.
Primary Biliary Cholangitis (PBC)Estonia - RecruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of the oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP inhibitor (PARPi) niraparib in adult participants with solid tumors.
This study looks at a new drug, GSK4524101, combined with an existing cancer drug, niraparib (Zejula), for adults with solid tumours. It aims to find a safe dose and see how well the combination shrinks tumours and manages cancer.
NeoplasmsEstonia - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseEstonia - Enrolling by invitationPHASE3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study looks at a new treatment called Selatogrel for people who have recently had a heart attack and are at risk of another. It checks if taking Selatogrel when symptoms start can help prevent a second heart attack.
Acute Myocardial InfarctionEstonia - Recruiting
Fabry Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Fabry disease over time, including pregnant women. It helps doctors better understand the disease and improve care, without giving any new treatments. It's about observing, not experimenting.
Fabry DiseaseEstonia - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesEstonia - Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
Unresectable Hepatocellular CarcinomaEstonia - Active not recruitingPHASE3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
This study looks at the long-term safety and effectiveness of a medicine called ofatumumab for people with relapsing MS. It also checks how well vaccines work in people taking this medicine, including those for flu, pneumonia, tetanus, and COVID-19.
Relapsing Multiple SclerosisEstonia - RecruitingPHASE3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
This study is looking into a new treatment called GB-0895 for teenagers and adults with severe asthma that isn't well-controlled by usual medicines. Participants will receive either GB-0895 or a dummy treatment over about a year to see if it improves their health.
Severe AsthmaEstonia - Active not recruitingPHASE3
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
This study is looking at a specific shingles vaccine in older adults. It wants to see how well the vaccine continues to protect against shingles for many years, how strong the body's immune response remains, and if it's still safe over a long time.
Herpes ZosterEstonia - RecruitingPHASE3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
This study looks at a new treatment called dostarlimab for certain types of colon cancer that haven't spread. It compares dostarlimab with standard treatments to see if it works better before and after surgery to help patients.
Colonic NeoplasmsNeoplasms, ColonEstonia - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseEstonia - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseEstonia